| Management target | Revenue 14.0% FY27 |
|---|
| Revenue growth | 13% YoY consolidated revenue growth; domestic formulations up 14%. |
|---|---|
| Margins | Gross margins compressed by biologics mix; EBITDA margin at 35%. |
| Demand visibility | Strong chronic demand; Semaglutide adoption slower than initially expected. |
| Management confidence | Confident in biologics pivot despite short-term margin headwinds. |
Growth
Revenue grew 13% YoY; domestic formulations up 14%. Biologics and insulin growing faster but at lower margins.
Outlook
Guiding 14% revenue growth for FY27, aiming to outperform 11% market growth by 300 bps.
Risks
Gross margin compression due to product mix; slow Semaglutide patient adoption; Swiss Parentals remediation costs.
Earnings Call Transcript filed with BSE, NSE: ERIS. Summary written with AI assistance from the document.
Eris Lifesciences Ltd: key numbers
- Share price
- ₹1,258.90
- Market cap
- ₹17,466 Cr
- Revenue (annual)
- ₹3,129 Cr
- Net profit (annual)
- ₹619.5 Cr
- P/E (TTM)
- 27.1×Sector 50.4×
- Promoter holding
- 54.14%+0.22% QoQ
- FII holding
- 5.76%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Eris Lifesciences Ltd
All →Eris Lifesciences Annual General Meeting
Eris Lifesciences Limited conducted its 20th Annual General Meeting on September 25, 2026. Shareholders transacted business including the adoption of audited financial statements and director re-appointments.
Eris Lifesciences Employee Stock Options
Eris Lifesciences allotted 1,55,264 equity shares upon the exercise of employee stock options under its ESOP-2021 scheme.
Eris Lifesciences Management Change
Eris Lifesciences appointed Mr. Akhil Awasthi as Non-Executive Independent Director effective September 26, 2026 for a five-year term, subject to shareholder approval. No monetary value is associated with the appointment.
Eris Lifesciences Management Change
Mr. Krishnakumar Vaidyanathan has resigned as Executive Director and Chief Operating Officer of Eris Lifesciences Limited, effective September 30, 2026.
Eris Lifesciences Price Movement Clarification
Eris Lifesciences issued a clarification regarding media reports about its loan amount. It advised investors to rely only on the company's official exchange disclosures.
Eris Lifesciences Debt & Borrowing: ₹45 Cr
Eris Lifesciences has entered into a term loan agreement with Axis Bank Limited for ₹45 Crore to meet general liabilities.
- Value
- ₹45.00 Cr